FGF21 Reverses Mouse Obesity Through Hindbrain Circuit
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Oklahoma researchers discovered that the hormone FGF21 reverses obesity in mice by acting on a newly identified brain circuit in the hindbrain, specifically the nucleus of the solitary tract (NTS) and area postrema, which then communicate with the parabrachial nucleus.
- Lead researcher Matthew Potthoff, Ph.D., a professor of biochemistry and physiology at OU College of Medicine and deputy director of OU Health Harold Hamm Diabetes Center, said the team expected to find the signal in the hypothalamus and was "very surprised" to discover it was in the hindbrain instead.
- Unlike GLP-1 drugs like Ozempic and Wegovy, which act in the same hindbrain region but suppress appetite and food intake, FGF21 ramps up metabolic activity to help the body burn more energy and lose weight.
- FGF21 analogues are already being tested in clinical trials for MASH (metabolic dysfunction-associated steatohepatitis), a serious form of fatty liver disease, giving the new circuit findings immediate translational relevance.
- Potthoff said pinpointing the specific brain circuit could enable creation of more targeted therapies that avoid the side effects of current FGF21 analogues, which include gastrointestinal issues and, in some cases, bone loss.
- The findings were published in Cell Reports (2026, Vol. 45, Issue 4, DOI: 10.1016/j.celrep.2026.117093), and the team noted additional studies are needed to determine whether the same circuit also mediates FGF21's ability to reverse MASH.
Why it matters: The discovery gives drug developers a specific neural target for next-generation obesity and MASH treatments, and it reframes the brain's hindbrain as a hub where two major weight-loss mechanisms converge — one killing appetite, the other burning energy. For the estimated hundreds of millions of adults with obesity or fatty liver disease, the hope is a therapy that delivers weight loss without the GI side effects or bone loss tied to current FGF21 analogues.
